Northwest Biotherapeutics, the US-listed biotech company in which Neil Woodford holds a 25% stake, has admitted its plans to improve financial controls are "uncertain" amid reports it is incapable of policing internal fraud.
Its latest annual report, the group, which has seen shares plunge 90% since last Summer, revealed seven "material weaknesses" in its financial controls and said its plans to improve these were "uncertain," according to The Sunday Times. It reportedly admitted a "lack of controls to ensure that all material transactions and developments are properly recorded". Woodford's funds hit by September biotech sell-off This follows allegations the company's chief executive, Linda Powers, has transferred millions of dollars from Northwest into other businesses she controls. The company, wh...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes